Prescribers remain cautious about substituting generic versions of narrow therapeutic index (NTI) drugs due to risks of therapeutic failure or toxicity. Despite FDA assurances, doctors, pharmacists, and patients report real-world concerns that influence prescribing and dispensing practices.